Расширенный поиск

Туберкулез с широкой лекарственной устойчивостью микобактерий и ВИЧ-инфекция

Полный текст:


Туберкулез с широкой лекарственной устойчивостью микобактерий и ВИЧ-инфекция.

Об авторе

В. С. Боровицкий
Федеральное казенное учреждение "Лечебное исправительное учреждение № 12" Управления федеральной службы исполнения наказаний РФ по Кировской области

врач-фтизиатр учреждения 

613040, Кировская обл., г. Кирово-Чепецк. Тел.: (83361) 4-60-39, доп. 2-29.

Список литературы

1. Рекомендации по лечению резистентных форм туберкулеза. Пер. с англ. Женева: ВОЗ; 1998.

2. Migliori G.B., Besozzi G., Girardi E. et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur. Respir. J. 2007; 30 (4): 623–626.

3. Dheda K., Warren R. M., Zumla A. et al. Extensively drugresistant tuberculosis: epidemiology and management challenges. Infect. Dis. Clin. N. Am. 2010; 24 (3): 705–725.

4. Zwolska Z., Augustynowicz+Kopec E. Drug resistant tuberculosis. Pol. Merkur. Lekarski 2011; 30 (179): 362–366.

5. Martinson N.A., Chaisson R.E. Survival in XDR TB: shifting the curve and shifting the paradigm. J. Acquir. Immune Defic. Syndr. 2011; 57 (2): 89–91.

6. Gandhi N.R., Nunn P., Dheda K. et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 375 (9728): 1830–1843.

7. Badoum G., Saleri N., Dembele M.S. et al. Failing a re-treatment regimen does not predict MDR / XDR tuberculosis: is "blind" treatment dangerous? Eur. Respir. J. 2011; 37 (5): 1283–1285.

8. Chakroborty A. Drug-resistant tuberculosis: an insurmountable epidemic? Inflammopharmacology 2011; 19 (3): 131–137.

9. Loddenkemper R., Hauer B. Drug-resistant tuberculosis: a worldwide epidemic poses a new challenge. Dtsch. Arztebl. Int. 2010; 107 (1–2): 10–19.

10. Migliori G.B, Dheda K., Centis R. et al. Review of multidrug–resistant and extensively drug-resistant TB: global perspectives with a focus on sub-Saharan Africa. Trop. Med. Int. Hlth 2010; 15 (9): 1052–1066.

11. Prasad R. Revised National Tuberculosis Control Programme: current scenario. J. Indian Med. Assoc. 2009; 107 (10): 725–727.

12. Small P.M. Tuberculosis: a new vision for the 21st century. Kekkaku 2009; 84 (11): 721–726.

13. Mukherjee A., Lodha R., Kabra S. K. Changing trends in childhood tuberculosis. Indian J. Pediatr. 2011; 78 (3): 328–333.

14. Karim K. Tuberculosis and infection control. Br. J. Nurs. 2011; 20 (17): 1128, 1130–1133.

15. Carvalho A.C., Migliori G.B., Cirillo D.M. Tuberculosis in Europe: a problem of drug resistance or much more? Exp. Rev. Respir. Med. 2010; 4 (2): 189–200.

16. Fears R., Kaufmann S., Ter Meulen V. et al. Drug-resistant tuberculosis in the European Union: opportunities and challenges for control. Tuberculosis (Edinb.) 2010; 90 (3): 182–187.

17. Matteelli A., Richardson M. D., Sotgiu G. et al. Multidrugand extensively drug-resistant TB in persons living with HIV. Exp. Rev. Respir. Med. 2009; 3 (3): 245–254.

18. Monedero I., Caminero J.A. MDR-/XDR-TB management: what it was, current standards and what is ahead. Exp. Rev. Respir. Med. 2009; 3 (2): 133–145.

19. Symons G., Shean K., Pietersen E. et al. A historical review of XDR tuberculosis in the Western Cape province of South Africa. S. Afr. Med. J. 2011; 101 (9): 636–638.

20. Calver A. D., Falmer A. A., Murray M. et al. Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence/ South Africa. Emerg. Infect. Dis. 2010; 16 (2): 264–271.

21. Kvasnovsky C. L, Cegielski J. P., Erasmus R. et al. Extensively drug-resistant TB in Eastern Cape, South Africa: high mortality in HIV-negative and HIV-positive patients. J. Acquir. Immune Defic. Syndr. 2011; 57 (2): 146–152.

22. Dheda K., Shean K., Zumla A. et al. Early treatment outcomes and HIV status of patients with extensively drugresistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010; 375 (9728): 1798–1807.

23. Vella V., Racalbuto V., Guerra R. et al. Household contact investigation of multidrug-resistant and extensively drugresistant tuberculosis in a high HIV prevalence setting. Int. J. Tuberc. Lung Dis. 2011; 15 (9): 1170–1175.

24. Andrews J.R., Shah N.S., Weissman D. et al. Predictors of multidrug- and extensively drug-resistant tuberculosis in a high HIV prevalence community. PLoS One 2010; 5 (12): 15735.

25. Heysell S.K., Thomas T.A., Gandhi N.R. et al. Blood cultures for the diagnosis of multidrug-resistant and extensively drug-resistant tuberculosis among HIV-infected patients from rural South Africa: a cross-sectional study. BMC Infect. Dis. 2010; 10: 344.

26. Gandhi N.R., Shah N.S., Andrews J.R. et al. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am. J. Respir. Crit. Care Med. 2010; 181 (1): 80–86.

27. Cox H.S., McDermid C., Azevedo V. et al. Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South Africa. PLoS One 2010; 5 (11): 13901.

28. Thomas T.A., Shenoi S.V., Heysell S.K. et al. Extensively drug-resistant tuberculosis in children with human immunodeficiency virus in rural South Africa. Int. J. Tuberc. Lung Dis. 2010; 14 (10): 1244–1251.

29. Heysell S.K, Moll A.P., Gandhi N.R. et al. Extensively drugresistant Mycobacterium tuberculosis from aspirates, Rural South Africa. Emerg. Infect. Dis. 2010; 16 (3): 557–560.

30. Van der Plas H., Mendelson M. High prevalence of comorbidity and need for up-referral among inpatients at a district-level hospital with specialist tuberculosis services in South Africa: the need for specialist support. S. Afr. Med. J. 2011; 101 (8): 529–532.

31. Moodley P., Shah N. S., Tayob N. et al. Spread of extensively drug-resistant tuberculosis in KwaZulu-Natal province, South Africa. PLoS One 2011; 6 (5): 17513.

32. Lopes T., Gomes C., Diogo N. Tuberculosis unit: case study of 10 years of activity (1999–2009). Rev. Port. Pneumol. 2011; 17 (6): 266–271.

33. Rajasekaran S., Chandrasekar C., Mahilmaran A. et al. HIV coinfection among multidrug resistant and extensively drug resistant tuberculosis patients – a trend. J. Indian Med. Assoc. 2009; 107 (5): 281–282, 284–286.

34. Chakraborty N., De C., Bhattacharyya S. et al. Drug susceptibility profile of Mycobacterium tuberculosis isolated from HIV infected and uninfected pulmonary tuberculosis patients in eastern India. Trans. Roy. Soc. Trop. Med. Hyg. 2010; 104 (3): 195–201.

35. Balaji V., Daley P., Anand A.A. et al. Risk factors for MDR and XDR-TB in a tertiary referral hospital in India. PLoS One 2010; 5 (3): 9527.

36. Masjedi M.R., Tabarsi P., Baghaei P. et al. Extensively drugresistant tuberculosis treatment outcome in Iran: a case series of seven patients. Int. J. Infect. Dis. 2010; 14 (5): 399–402.

37. Tabarsi P., Chitsaz E., Baghaei P. et al. Impact of extensively drug-resistant tuberculosis on treatment outcome of multidrug-resistant tuberculosis patients with standardized regimen: report from Iran. Microb. Drug Resist. 2010; 16 (1): 81–86.

38. Tang S., Zhang Q., Yu J. et al. Extensively drug-resistant tuberculosis at a tuberculosis specialist hospital in Shanghai, China: clinical characteristics and treatment outcomes. Scand. J. Infect. Dis. 2011; 43 (4): 280–285.

39. Jarand J., Shean K., O'Donnell M. et al. Extensively drugresistant tuberculosis (XDR-TB) among health care workers in South Africa. Trop. Med. Int. Hlth. 2010; 15 (10): 1179–1184.

40. O'Donnell M.R., Jarand J., Loveday M. et al. High incidence of hospital admissions with multidrug-resistant and extensively drug-resistant tuberculosis among South African health care workers. Ann. Intern. Med. 2010; 153 (8): 516–522.

41. LoBue P. Extensively drug-resistant tuberculosis. Curr. Opin. Infect. Dis. 2009; 22 (2): 167–173.

42. Lawn S.D., Wood R. Antiretroviral therapy for control of the HIV-associated MDR and XDR tuberculosis epidemic in South Africa. Am. J. Respir. Crit. Care Med. 2010; 182 (12): 1567; author reply 1568–1569.

43. Amaral L., Molnar J. Therapy Of XDR TB with thioridazine a drug beyond patent protection but eligible for patent "as new use". Recent Pat. Antiinfect. Drug Discov. 2010; 5 (2): 109–114.

44. Huang Q., He R., Kozikowski A. P. Stereochemistry at the forefront in the design and discovery of novel anti-tuberculosis agents. Curr. Top. Med. Chem. 2011; 11 (7): 810–818.

45. Pieroni M., Tipparaju S.K., Lun S. et al. Pyrido[1,2-a]benzimidazole-Based Agents Active Against Tuberculosis (TB), Multidrug-Resistant (MDR) TB and Extensively Drug-Resistant (XDR) TB. ChemMedChem. 2011; 6 (2): 334–342.

46. Bakal R.L., Gattani S.G. Identification and development of 2,5-disubstituted oxadiazole as potential candidate for treatment of XDR and MDR tuberculosis. Eur. J. Med. Chem. 2012; 47 (1): 278–282.

47. Cole S.T., Riccardi G. New tuberculosis drugs on the horizon. Curr. Opin. Microbiol. 2011; 14 (5): 570–576.

48. Igarashi M., Takahashi Y. Developmental status of new antituberculous drugs. Nihon Rinsho 2011; 69 (8): 1482–1488.

49. Sarkar S., Suresh M.R. An overview of tuberculosis chemotherapy – a literature review. J. Pharm. Pharm. Sci. 2011; 14 (2): 148–161.


Для цитирования:

Боровицкий В.С. Туберкулез с широкой лекарственной устойчивостью микобактерий и ВИЧ-инфекция. Пульмонология. 2013;(2):109-113.

For citation:

Borovitsky V.S. Multi-drug resistant tuberculosis and HIV-infection. PULMONOLOGIYA. 2013;(2):109-113. (In Russ.)

Просмотров: 748

ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)